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High Telomerase Activity in
Neutrophils From Unstable Coronary Plaques
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Antonella Farsetti, MD,¶ Antonino Mulè, MD,† Giovanna Liuzzo, MD,* Giuseppe La Torre, MD,§
Giampaolo Niccoli, MD,* Rocco Mongiardo, MD,* Alfredo Pontecorvi, MD,‡
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Objectives We evaluated telomerase activity in circulating polymorphonuclear neutrophils (PMN) and in PMN isolated from
coronary atherosclerotic plaques by a novel approach.
Background Delayed apoptosis of PMN have been demonstrated in unstable angina (UA). These cells have a finite lifespan
with low telomerase activity, a polymerase that extends telomeres, structures essential for cell aging. Reactiva-
tion of telomerase has been associated with resistance to apoptosis.
Methods We studied 20 patients with UA and 6 patients with chronic stable angina (SA), undergoing a percutaneous coro-
nary intervention. Circulating PMN were isolated from venous blood and PMN derived from coronary plaque were
isolated from washing medium of angioplasty balloons.
Results Telomerase activity was higher in coronary plaque PMN of UA patients than in coronary plaque PMN of SA patients
(122.7, range 20.5 to 3,696; and 47.7, range 16 to 212.6, respectively, p 0.001) and higher than in peripheral
PMN of SA patients (122.7, range 20.5 to 3,696 vs. 59, range 16.5 to 132.5, p 0.001). We found a statistically
significant difference between venous and coronary plaque PMN telomerase activity in UA patients (z  2.875;
p  0.004). Among UA patients, a shorter time interval from symptom onset to coronary PMN sampling was the
only independent predictor of high telomerase activity in coronary plaque PMN (p 0.001, R2  0.75).
Conclusions In UA patients, telomerase activity is high in coronary plaque PMN, while it is low in peripheral PMN. Telomerase
reactivation in resident PMN resulting in a prolonged lifespan might play a key role in the early phases of
instability. (J Am Coll Cardiol 2007;50:2369–74) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.08.048e
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helomeres are specialized deoxyribonucleic acid (DNA)-
rotein structures that contain noncoding TTAGGG re-
eats and associated proteins, essential for chromosome
tability. Depending upon the cellular context, telomere
hortening may lead to cell senescence or apoptosis. Telo-
ere maintenance is primarily achieved by telomerase, a
ibonucleoprotein with reverse transcriptase activity that
ses its internal ribonucleic acid component as a template
or the synthesis of telomeric DNA. Telomerase activity is
resent during early development and in adult germline and
tem cells of self-renewing tissues, but absent or functionally
nsufficient in adult somatic cells. In the absence of the
rom the *Institute of Cardiology, †Division of Anatomic Pathology and Histology,
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ational Council of Research, Rome, Italy; and the ¶Department of Experimental
ncology, Regina Elena Cancer Institute, Rome, Italy. This work was partially
upported by “Associazione Italiana Ricerca sul Cancro.”i
Manuscript received April 16, 2007; revised manuscript received August 6, 2007,
ccepted August 13, 2007.nzyme, telomeres shorten with cell division, a process that
ay act as a mitotic clock and signal entry into senescence.
hortening of telomeres is thus held responsible for the
imited lifespan of somatic cells in culture and has also been
ssociated with organismal aging (1–3). The mechanisms
hereby telomerase controls these processes are beginning
o be understood and include effects on the signaling
ascades that regulate apoptosis. Indeed, inhibition of te-
omerase and the ensuing telomere shortening below a
ritical length results in apoptosis in various cell types,
hereas induction of telomerase activity is associated with
esistance to apoptosis (4,5).
In particular, polymorphonuclear neutrophils (PMN)
ave a finite lifespan and typically die by undergoing
poptosis. Thus, PMN apoptosis represents a control mech-
nism limiting the toxic potential of these short-lived,
erminally differentiated cells (6,7). Post-mortem studies
ave recently shown PMN infiltration in unstable but notn stable atherosclerotic plaques, suggesting their possible
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Telomerase Activity in Coronary Plaque Neutrophils December 18/25, 2007:2369–74role in destabilization of coro-
nary plaque (8). Accordingly,
several clinical studies have
consistently demonstrated that
acute coronary syndromes are as-
sociated with systemic evidence
of PMN activation (9–12). More
recently, Garlichs et al. (13) ob-
served systemic activation and de-
layed apoptosis of PMN in pa-
tients with unstable angina (UA)
as compared with patients with
stable angina (SA).
In order to characterize the
echanism of delayed PMN apoptosis in acute coronary
yndromes, we assayed telomerase activity in PMN isolated
rom peripheral blood in patients with chronic SA and in
atients with UA. In the same patients, we also evaluated
elomerase activity in PMN isolated directly from coronary
therosclerotic plaques obtained during percutaneous coro-
ary intervention (PCI), using a novel technique.
ethods
tudy population. We enrolled 26 consecutive patients
ndergoing PCI: 20 patients with Braunwald class IIB or
IIB UA and 6 patients with SA for at least 6 months before
dmission. We excluded all subjects with chronic or acute
nfections or an inflammatory condition, as defined else-
here (14). Patient characteristics are reported in Table 1
15).
The protocol was approved by the ethics committee of
he Catholic University of Rome, and all patients gave
ritten informed consent.
eripheral cell isolation. During coronary angiography, all
atients underwent blood sampling from the right femoral
rtery and vein. Peripheral blood PMN were isolated by a
ingle-step density gradient procedure using Polymor-
hprep separation medium (Nycomed Pharma AS, Oslo,
orway). After centrifugation at 500  g for 30 min at
0°C, the mononuclear cell band and PMN were retrieved
nd washed twice in phosphate-buffered saline. Contami-
ating erythrocytes were removed by hypotonic lysis. Pe-
ipheral PMN pellets were stored at 80°C.
oronary plaque cell isolation and PMN identification.
fter coronary angiography, all unstable patients underwent
CI on the culprit stenosis and stable patients on at least 1
ritical stenosis. A standard dose of heparin (5,000 IU) was
sed in all patients. Stent deployment was preceded by
redilation, and angioplasty balloons used for predilation
ere similar in the 2 groups of patients (Maverick, Boston
cientific, Natick, Massachusetts). Our novel protocol for
MN collection was characterized by the following steps:
. Inflation of pre-dilation balloon for 20 s at a mean of 10
Abbreviations
and Acronyms
DNA  deoxyribonucleic
acid
PCI  percutaneous
coronary intervention
PMN  polymorphonuclear
neutrophils
SA  stable angina
TRAP  telomeric repeat
amplification protocol
UA  unstable angina(6 to 14) atmospheres (. Deflation of pre-dilation balloon that was immediately
pulled back inside the guiding catheter and collected in
appropriate tubes with 5 ml of Cytolyt solution (Cytyc
Corp., Boxborough, Massachusetts)
he persistency time of balloon inside the guiding catheter
as extremely short, 5 s, thus minimizing the possibility
f contamination by blood constituents.
In order to confirm the plaque source of PMN, we tested
n a subgroup of patients the presence of these inflammatory
ells after inflating the balloon inside the guiding catheter,
laced in the ascending aorta for the same duration and
nflation pressure. We failed to find PMN from this
ashing medium isolated by the same technique.
After centrifugation of washing medium at 1,200  g for
0 min, the cell pellet was added to 20 cc of PreservCyt
olution (Cytyc Corp.) in a plastic tube mounted on a
olarized microscope slide. Several sedimentation intervals
ere tested, and the optimal PMN isolation was obtained
ith 4-h decantation. The procedure based on different cell
edimentation velocity yielded a minimum of 50 up to 200
MN (mean 125) per slide, corresponding to 90% of the
otal cellularity. Immunocytochemistry with myeloperoxi-
ase MPO-7 (Dako Laboratories, Glostrup, Denmark)
ntibodies was performed to confirm PMN morphological
eatures. The immunocytological staining was performed
sing a standard streptavidin-biotin-peroxidase method
emographic and Clinicalharacteristics of Pat ents
Table 1 Demographic and ClinicalCharacteristics of Patients
Unstable
Angina
(n  20)
Stable
Angina
(n  6)
p
Value
Age (yrs) 67  9 67  8 NS
Gender (M/F) 3/20 2/6 NS
Risk factors , n (%)
Family history of IHD 5 (25%) 1 (16%) NS
Hypercholesterolemia 13 (65%) 5 (83%) NS
Diabetes 8 (40%) 2 (33%) NS
Hypertension 16 (80%) 3 (50%) NS
Obesity (BMI 25 kg/m2) 3 (15%) 1 (16%) NS
Smoking (current status) 0 (0%) 0 (0%) NS
Medication, n (%)
Beta-blockers 18 (90%) 5 (83%) NS
Calcium blockers 6 (30%) 3 (50%) NS
ACE inhibitors 13 (65%) 4 (66%) NS
Aspirin 17 (85%) 4 (66%) NS
Other antiplatelet agents 16 (80%) 3 (50%) NS
Lipid-lowering therapy 18 (90%) 6 (100%) NS
Hormonal therapy* 1 (5%) 2 (33%) NS
Coronary angiographic lesions†, n (%)
Type A 5 (25%) 3 (50%) NS
Type B 13 (65%) 3 (50%) NS
Type C 2 (10%) 0 (0%) NS
Hormonal therapy is represented by finasteride, a type 2 5alpha-reductase inhibitor; †Coronary
ngiographic lesions are classified according to morphology in type A, B, and C (15).
ACE  angiotensin-converting enzyme; BMI  body mass index; IHD  ischemic heart disease.DAKO, Copenhagen, Denmark) (Fig. 1).
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December 18/25, 2007:2369–74 Telomerase Activity in Coronary Plaque NeutrophilsAs a control we used washing medium of the distal
ortion of dilatation catheter without balloon in 6 cases; in
hese cases we did not obtain PMN but red blood cells from
he washing medium.
elomeric repeat amplification protocol (TRAP). Te-
omerase activity was analyzed using the TRAP described by
im et al. (16). Briefly, extracts from peripheral or coronary
MN were prepared by detergent lysis. After incubation on
ce, the lysate was centrifuged, and the supernatant was
mmediately used to evaluate telomerase activity in this
ssay. The reaction was carried out using 2 g of protein
xtractions in 50 l of reaction mixture, to which an internal
elomerase assay standard was added for estimation of
elomerase activity and identification of any false-negative
amples containing Taq polymerase inhibitors.
Similar results were obtained using different concentra-
ions (0.2, 0.5, 1, 2, 5, and 10 g) of protein extracts (data
ot shown). Quantitative analysis was performed with the
mageJ 1.24 software (National Institutes of Health, Be-
hesda, Maryland), and telomerase activity was quantified by
easuring the signals of telomerase ladder bands and
xpressed as densitometric values. The relative telomerase
ctivity was calculated as the ratio to the internal standard.
s positive and negative controls, 0.1 g of protein from
elomerase-positive HeLa cells was assayed before and after
eat inactivation. All assays were performed by a single
nvestigator, who was blinded to patients’ characteristics.
tatistical analysis. Chi-square test was used for compar-
ng the frequency distribution of categorical variables among
roups. Telomerase activity values were not normal distrib-
ted, and the data are reported as medians and ranges.
Comparisons of variables not showing normal distribu-
Figure 1 Immunostaining of Coronary Plaque
PMN With Myeloperoxidase Antibodies
Immunostaining for myeloperoxidase MPO-7 antibodies (purple) reveals stain-
ing of all cells isolated by direct washing of angioplasty balloon used for coro-
nary revascularization, indicating that MPO-7–positive cells are neutrophils
(arrow). Original magnification: 444. PMN  polymorphonuclear neutrophils.ion between UA and SA patients were performed with pruskal-Wallis test; in the case of overall between-groups
ignificant differences at Kruskal-Wallis test, direct compar-
sons were performed by Mann-Whitney test, with Bonfer-
oni correction.
Within-subjects comparisons of variables not showing
ormal distribution in the 2 populations were performed
ith paired nonparametric Wilcoxon signed rank test.
Univariate correlation between telomerase activity and
ther variables was performed using nonparametric Spear-
an rank test.
Multivariate analysis was performed using linear regres-
ion after log transformation of the dependent variable,
elomerase activity, since the distribution was skewed. We
sed a stepwise procedure (backward elimination) including
n the model age and gender (as potential confounders or
ffect modifiers) and parameters that at univariate analysis
ere related to telomerase activity (p 0.10). The goodness
f fit of the model was assessed using the R2 statistic and the
istribution of the unstandardized residuals. The signifi-
ance level for p was set at p  0.05. The statistical analysis
as performed using SPSS software, release 12.0 (SPSS
nc., Chicago, Illinois).
esults
elomerase activity, measured by TRAP assay, in PMN
solated from venous, arterial blood or by direct washing of
ngioplasty balloons was represented in Figure 2. Extracts
rom PMN isolated by direct washing of angioplasty bal-
oons showed high telomerase activity in UA patients.
elomerase activity was barely detectable in PMN derived
rom angioplasty balloons of patients with SA and in PMN
erived from venous and arterial blood of patients with UA
nd SA (Fig. 2).
Telomerase activity was higher in coronary plaque PMN
f patients with UA than in coronary plaque PMN of
atients with SA (122.7, range 20.5 to 3,696; and 47.7,
ange 16 to 212.6, respectively, p  0.001) and higher than
n peripheral PMN of SA patients (122.7, range 20.5 to
,696 vs. 59, range 16.5 to 132.5, p  0.001). Particularly,
e found a statistically significant difference between venous
nd coronary plaque PMN telomerase activity in UA
atients (z  2.875, p  0.004) (Fig. 3).
Telomerase activity in arterial PMN was similar to that
bserved in venous PMN (data not shown).
Among UA patients, a significant inverse correlation (p
0.001) between telomerase activity in coronary plaque
MN and time interval from last episode of angina and
MN sampling by direct washing of angioplasty balloons
as found at univariate analysis. In contrast, no correlation
as found between cardiovascular risk factors, medical
herapy, angiographic type of coronary lesions, and telom-
rase activity (Table 2). At multiple linear regression anal-
sis, the following variables were included in the model:
ime interval from last episode of angina and coronary
laque PMN sampling, diabetes, age, and gender; time
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Telomerase Activity in Coronary Plaque Neutrophils December 18/25, 2007:2369–74nterval from the last episode of angina and coronary plaque
MN sampling remained the only independent predictor of
elomerase activity in coronary plaque PMN (p  0.001, R2
0.75) (Fig. 4).
Six of 20 patients (30%) with a diagnosis of UA expressed
ery high telomerase activity in comparison with the re-
aining 14 patients (respectively 2,194, range 806 to 3,696;
nd 115, range 20.5 to 390). Interestingly, high telomerase
A patients were different from low telomerase UA patients
nly in the time interval from the last anginal episode and
onsequent PMN sampling (p  0.003).
iscussion
ur study demonstrates, for the first time, high telomerase
ctivity in PMN from coronary plaque of patients with UA,
ut not from patients with SA nor in PMN from peripheral
lood. Notably, in patients with UA, the only predictor of
elomerase activity in the coronary atherosclerotic plaque
as a shorter time interval from symptom onset to PMN
ollection, supporting a possible role of telomerase reacti-
Figure 2 High Telomerase Activity in
Coronary Plaque PMN of Patients With UA
Cell extracts derived from polymorphonuclear neutrophils (PMN) isolated from
arterial (A) or venous blood (V) or directly from angioplasty balloons (AB) of
unstable angina (UA) and chronic stable angina (SA) patients were assayed for
telomerase activity by telomeric repeat amplification protocol assay in the pres-
ence of internal control (IC) (36 base pairs). As positive and negative controls,
cell extracts (0.1 g) from telomerase-positive HeLa cells were assayed before
and after heat inactivation (HeLa and HeLa H.I.), respectively. Panels relative
to the IC are shown at a lower detection exposure. Telomerase activity was
barely detectable in PMN of patients with chronic SA (lanes 1 to 6, 13, and
14) and in arterial and venous PMN in patients with UA (lanes 8 and 9 and 11
and 12). In contrast, telomerase activity was high in PMN from the coronary
atherosclerotic plaques in patients with UA (lanes 7 and 10).ation in PMN persistence in the plaque during the earlyhases of coronary instability. Particularly, in all patients
ith telomerase activity higher than the highest found in
A, the time interval from last anginal episode to coronary
MN sampling was 40 h.
Therefore, in unstable patients with recent coronary
nstability, the survival of local activated PMN could be
rolonged by telomerase reactivation confined to coronary
laque PMN. This mechanism is likely to exacerbate tissue
amage and oxidative stress due to PMN activity and to
aintain active the inflammatory process, as neutrophil
poptosis has been identified as one of the key mechanism
o switch off inflammation.
Activation status of PMN derived from coronary plaques
as not measured for the limited number of cells obtained
y our new approach (a minimum of 50 up to 200
eutrophils per slide). However, as telomerase reactivation
ppears to play a key role in delaying apoptosis and inducing
rowth of cancer cells (17), this intracellular mechanism
ould also prolong coronary plaque PMN activity merely by
xtending their local lifespan.
The observation that high telomerase activity is demon-
trable in coronary plaque PMN of a subset of UA patients,
n whom the measurements were made within 40 h of the
ast anginal episode, is open to multiple interpretations.
his phenomenon might suggest that high telomerase
ctivity plays a key role in triggering coronary instability and
s then lost over time. It might represent, however, an
nconstant epiphenomenon.
Figure 3 Distribution of Telomerase Activity
Telomerase activity in polymorphonuclear neutrophils derived from venous blood
(V) or from washing medium of angioplasty balloons (AB) is represented as dot
plots.
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December 18/25, 2007:2369–74 Telomerase Activity in Coronary Plaque NeutrophilsNormal human PMN, like other somatic cells, divide a
imited number of times before entering a nondividing state
alled replicative senescence. Telomerase is normally inhib-
ted in these inflammatory cells (18,19). Our study is in
eeping with these previous studies, showing that telomer-
se activity was barely detectable in circulating PMN, but
elomerase reactivation in these cells is possible (20) and
ould represent a way to overcome replicative senescence
5). In our study, the evidence of high telomerase activity in
MN from coronary atherosclerotic plaque suggests a local
rocess leading to intracellular enzyme reactivation resulting
n prolonged survival of these inflammatory cells, as typically
bserved in cell types that retain high proliferative potential
21–23). Indeed, telomere dynamics and changes in telom-
rase activity are consistent elements associated with
hanges in proliferative state. Particularly, highly specific
orrelations and early causal relationships exist between telom-
rase activation and indefinite cell proliferation (24–26).
We used a novel approach to collect in vivo PMN from
oronary atherosclerotic plaques. Our method yielded a
MN population with a purity 90%. This homogenous
ell composition is important to minimize noise in TRAP
ssay for evaluation of telomerase activity. In our study,
redictors of High Telomerase Activity inoronary Plaque Neutrophils in Unstable Angina
Table 2 Predictors of High Telomerase Activity inCoronary Plaque Neutrophils in Unstable Angina
Telomerase Activity (n  20)
Univariate Analysis
(p Value)
Multivariate Analysis
(p Value)
Age 0.65 0.09
Gender 0.40 0.9
Risk factors
Family history of IHD 0.27 *
Hypercholesterolemia 0.25 *
Diabetes 0.06 0.08
Hypertension 0.25 *
Obesity (BMI 25 kg/m2) 0.30 *
Smoking (current status) † *
Medication
Beta-blockers 0.20 *
Calcium blockers 0.36 *
ACE inhibitors 0.36 *
Aspirin 0.43 *
Other antiplatelet agents 0.39 *
Lipid-lowering therapy 0.23 *
Hormonal therapy‡ 0.93 *
PCI timing§ 0.001 0.001
Coronary angiographic lesions
Type A 0.47 *
Type B 0.40 *
Type C 0.69 *
Not performed for p  0.1 at univariate analysis (age and gender performed because of likely
elation to telomerase activity); †not performed on empty groups (smokers in UA group 0%);
hormonal therapy is represented by finasteride, a type 2 5alpha-reductase inhibitor; §percutane-
us coronary intervention (PCI) timing was defined as time interval between last anginal episode
nd polymorphonuclear neutrophil sampling; coronary angiographic lesions are classified accord-
ng to morphology in type A, B, and C (15).
Abbreviations as in Table 1.uman telomerase reverse transcriptase ribonucleic acidnalysis could not be performed because of the limited
umber of neutrophils available by direct washing of coro-
ary angioplasty balloons.
Our findings are in keeping with those of Naruko et al.
8) who analyzed neutrophils in coronary culprit stenosis
btained at autopsy in patients who had died of acute
yocardial infarction and in atherectomy specimens from
A and UA patients. Neutrophils were detected in 44% of
atients with UA and in only 6% of patients with SA.
Recently, reactivation of telomerase activity was observed
n vascular smooth muscle cells but not in areas of
onocyte-macrophage infiltrations in human atheroscle-
otic coronary plaque from heart transplant recipients (27).
ifferent mechanism of inflammation in transplanted hearts
nd in acute coronary syndrome might explain the different
attern of telomerase reactivation in our and in their study.
Garlichs et al. (13) have recently observed a marked delay
f circulating PMN apoptosis, in patients with acute coro-
ary syndromes, while, in our study, we failed to find high
elomerase activity in circulating PMN; as our findings
upport the notion that telomerase reactivation of PMN
rom coronary plaques is specifically related to mechanisms
perating at the level of atherosclerotic plaque but not in
ystemic PMN activation, we hypothesized that in patients
ith UA different mechanisms are responsible for PMN-
elayed apoptosis in coronary plaque milieu and in periph-
ral blood.
Figure 4 Linear Regression Between
Telomerase Activity And Timing of PCI
Among unstable angina patients, a significant inverse correlation was found
between telomerase activity (ln: natural logarithm) in polimorphonuclear neutro-
phils obtained by atherosclerotic plaques and time interval (h) between last
anginal episode and polimorphonuclear neutrophils sampling, during percutane-
ous coronary intervention (PCI).
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Telomerase Activity in Coronary Plaque Neutrophils December 18/25, 2007:2369–74An important limitation of our study is represented by the
recise origin of coronary PMN. Indeed, PMN might
heoretically come from coronary thrombus and not neces-
arily from the atherosclerotic plaque. This limitation,
owever, does not reduce the importance of our findings as
e demonstrate for the first time that a specific reactivation
f telomerase occurs only at the local level of the unstable
laque and not in the systemic circulation. Of note, systemic
ontamination of angioplasty balloons is unlikely, as telom-
rase activity was always absent in peripheral neutrophils.
A second limitation of our study is represented by the
mall sample size of SA patients, reflecting our policy of not
vertreating with PCI stable patients with a low risk of
uture events, in agreement with the results of the COUR-
GE (Clinical Outcomes Utilizing Revascularization and
ggressive DruG Evaluation) study (28).
In a previous study, Biasucci et al. (10) reported that
eutrophil activation (analyzed by intracellular myeloperox-
dase index) was present in 93% of UA patients but only in
2% of chronic SA patients, demonstrating a large effect
ize that could be translated to our study. This limitation is
ttenuated by the intraindividual assessment of telomerase
ctivity from plaque and from systemic circulation PMN,
hich strengthen the statistical significance of this study.
onclusions
n patients with UA, but not in patients with SA, significant
elomerase activity was detected in the coronary plaque but
ot in circulating PMN, in particular when PMN were
btained within a few hours of the last anginal episode.
hese findings suggest local extended lifespan and pro-
onged activity of these inflammatory cells in the early phase
f instability. Because of the toxic potential of PMN, this
echanism may represent a contributory pathway in the
athogenesis of instability. Further studies are warranted in
rder to establish the precise relationship between telomer-
se reactivation and neutrophil activity in the unstable
oronary plaques.
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